Physiological and immunological responses to measles vaccine

麻疹疫苗的生理和免疫反应

• 批准号: 9756312
• 负责人: Diane E Griffin
• 金额: $ 66.16万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2018
• 资助国家: 美国
• 起止时间: 2018-08-06 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9756312
• 关键词: Address; Amino Acid Substitution; Antibodies; Antibody Response; Antibody titer measurement; Attenuated; Attenuated Live Virus Vaccine; Attenuated Vaccines; Avidity; B-Lymphocytes; Biological; Biology; Blood; Bone Marrow; CD4 Positive T Lymphocytes; Cause of Death; Cells; Characteristics; Chicken Cells; Child; Communicable Diseases; Data; Development; Dose; Endothelial Cells; Epithelial Cells; Exanthema; Gene Proteins; Genetic Determinism; Hemagglutinin; Immune response; Immunity; Immunization; Immunoglobulin-Secreting Cells; Infection; Inhalation; Injections; Knowledge; Lymphocyte; Lymphoid; Lymphoid Cell; Lymphoid Tissue; Macaca; Macaca mulatta; Measles; Measles Vaccine; Measles virus; Modeling; Morbidity - disease rate; Myeloid Cells; Oncolytic; Pattern; Peripheral Blood Mononuclear Cell; Physiological; Plasmablast; Population; Process; Production; Productivity; Proteins; RNA; Recombinants; Rest; Safety; Sampling; Signal Transduction; Site; T cell response; T-Cell Immunologic Specificity; T-Lymphocyte; TLR2 gene; Testing; Time; Vaccines; Viral; Viremia; Virulence; Virulent; Virus; Virus Assembly; Virus Replication; attenuated measles virus; attenuation; cancer therapy; cell type; citrate carrier; in vivo; mortality; novel vaccines; respiratory; response; reverse genetics; tumor; vector; viral RNA

Summary Measles remains one of the most important causes of child morbidity and mortality worldwide. Studies of measles in children and in a well-characterized rhesus macaque model have shown that clearance of wild type (WT) measles virus (MeV) RNA is ongoing for many months after clearance of infectious virus with persistence in peripheral blood mononuclear cells and lymphoid tissues. RNA persistence is accompanied by ongoing immune stimulation with continued production of MeV-specific plasmablasts, antibody (Ab) maturation and multiple waves of functionally distinct T cells. These immune responses result in lifelong immunity to measles, but comparable data are not available for the live attenuated MeV vaccine. The MeV vaccine was developed empirically by attenuation of a WT MeV isolate by passage in chicken cells. The resultant live attenuated vaccine was licensed in 1963 and has been remarkably safe and successful although delivery by injection creates hurdles to sustained high coverage that might be alleviated with respiratory delivery. Its safety record, combined with advances in reverse genetics for negative strand viruses, have led to development of recombinant versions as vectors for immunization against other infections and as oncolytic agents for a variety of tumors. However, limited understanding of fundamental aspects of MeV vaccine virus in vivo biology hinders development. For instance, there is little knowledge of where the vaccine virus replicates, the mechanism(s) of attenuation of virulence or how the immune responses induced differ from those induced by WT infection except to note that antibody titers are lower and protection is less durable. We hypothesize that a central difference between infection with vaccine and WT strains is the ability to replicate and persist in lymphoid tissues. This proposal will address this knowledge gap by: 1) Identifying the target cell(s) in which vaccine virus replicates less well than WT virus. We hypothesize that attenuated replication is cell type-specific and that vaccine strains of MeV replicate well in myeloid, endothelial and epithelial cells, but poorly in lymphoid cells. 2) Identifying the viral determinants of inefficient MeV vaccine virus replication. We hypothesize that the hemagglutinin (H) and matrix (M) proteins are the primary determinants of inefficient replication in lymphocytes through effects on TLR2 signaling, virus assembly and release and will test the hypothesis by constructing recombinant strains of EZ vaccine that will tested for replication in lymphocytes. 3) Determining the in vivo sites of vaccine virus replication and dynamics of viral RNA clearance in rhesus macaques. We hypothesize that vaccine strains of MeV do not spread efficiently from lymphoid sites of infection and that both infectious virus and viral RNA are cleared quickly. 4) Identifying differences in the CD4+ T cell and Ab responses to infection with vaccine and WT MeV. We hypothesize that vaccine strains induce fewer MeV-specific Ab-secreting cells for a shorter period of time associated with a less robust and less polyfunctional CD4+ T cell response than WT strains.

总结